BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 17971483)

  • 1. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
    van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
    Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
    Wei J; Zhou XF; Zhao F; Zhou JF; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):111-6. PubMed ID: 19236759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.
    Chu SC; Wang TF; Li CC; Kao RH; Li DK; Su YC; Wells DA; Loken MR
    Leuk Res; 2011 Jul; 35(7):868-73. PubMed ID: 21397943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
    Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
    Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
    Germing U; Strupp C; Kuendgen A; Isa S; Knipp S; Hildebrandt B; Giagounidis A; Aul C; Gattermann N; Haas R
    Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Scoring analysis on prognosis of 63 patients with melodysplastic syndrome].
    Wei J; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):305-11. PubMed ID: 18426654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.
    Xu F; Li X; Chang CK; Guo J; Wu LY; He Q; Zhang Z; Zhu Y; Gu SC; Shi WH; Song LX; Su JY; Zhou LY; Zhang X; Wu D
    PLoS One; 2014; 9(2):e88706. PubMed ID: 24558415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic clustering of myelodysplastic syndromes.
    Maynadié M; Picard F; Husson B; Chatelain B; Cornet Y; Le Roux G; Campos L; Dromelet A; Lepelley P; Jouault H; Imbert M; Rosenwadj M; Vergé V; Bissières P; Raphaël M; Béné MC; Feuillard J;
    Blood; 2002 Oct; 100(7):2349-56. PubMed ID: 12239142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
    Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
    Malcovati L; Porta MG; Pascutto C; Invernizzi R; Boni M; Travaglino E; Passamonti F; Arcaini L; Maffioli M; Bernasconi P; Lazzarino M; Cazzola M
    J Clin Oncol; 2005 Oct; 23(30):7594-603. PubMed ID: 16186598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
    Cremers EMP; Westers TM; Alhan C; Cali C; Wondergem MJ; Poddighe PJ; Ossenkoppele GJ; van de Loosdrecht AA
    Eur J Cancer; 2016 Feb; 54():49-56. PubMed ID: 26720403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes.
    Xie W; Wang X; Du W; Liu W; Qin X; Huang S
    Cytometry A; 2010 Sep; 77(9):840-8. PubMed ID: 20662087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome.
    Ogata K; Nakamura K; Yokose N; Tamura H; Tachibana M; Taniguchi O; Iwakiri R; Hayashi T; Sakamaki H; Murai Y; Tohyama K; Tomoyasu S; Nonaka Y; Mori M; Dan K; Yoshida Y
    Blood; 2002 Dec; 100(12):3887-96. PubMed ID: 12393641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of immunophenotypic features of blasts in patients with myelodysplastic syndrome by flow cytometry and its diagnostic significance].
    Sun JF; Yang B; Zhang L; Huang Y; Yang J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):632-5. PubMed ID: 22739171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research advances in value of flow cytometric immunophenotyping in diagnosis and prognostic evaluation of myelodysplastic syndrome].
    Lu D; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):785-90. PubMed ID: 23815941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes.
    Xu F; Li X; Wu L; He Q; Zhang Z; Chang C
    Br J Haematol; 2010 May; 149(4):587-97. PubMed ID: 20331463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.